Chronic viral hepatitis

Medical Journal of Australia

Volumn 168, Issue 12, 1998, Pages 619-626

  Farrell, Geoffrey C ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; HEPATITIS VACCINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; VIRUS RNA;

CHRONIC HEPATITIS; DIET THERAPY; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION RISK; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; REVIEW;

EID: 0032526933     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1998.tb141451.x     Document Type: Review

References (31)

1. Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101: 613-616.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
3. Tsai SL, Chen MY, Yang PM, et al. Acute exacerbations of chronic hepatitis B are accompanied by increased T cell responses to hepatitis core and e antigens. J Clin Invest 1992; 89: 87-93.
4. Everhart JE, Hoofnagle J. Hepatitis B-related end-stage liver disease. Gastroenterology 1992; 103: 1692-1694.
5. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427.
6. Hope RL, Weltman M, Dingley J, et al. Interferon alfa for chronic active hepatitis B. Long term follow-up of 62 patients: outcomes and predictors of response. Med J Aust 1995; 162: 8-11.
7. Poynard T, Bedossa P, Opolon P, et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
8. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
9. Farrell GC. Hepatitis C: a current perspective. Aust Fam Physician 1995; 24: 321-329.
10. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26 (3 Suppl 1): 15S-20S.
11. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-620.
12. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterotogy 1988; 95: 734-739.
13. Davis GL. Treatment of chronic hepatitis B. Hepatology 1991; 14: 567-569.
14. Angus PW, Locarnini SA, McCaughan GW, et al. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 1995; 21: 14-18.
15. Nagamine T, Ohtuka T, Takehara K, et al. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996; 24: 135-140.
16. Gerberding JL. The infected health care provider. N Engl J Med 1996; 334: 594-595.
17. Kane JA, Kane SP, Jain S. Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 1995; 36: 146-148.
18. Drew AK, Myers SP. Safety issues in herbal medicine: implications for the health professions. Med J Aust 1997; 166: 538-541.
19. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323.
20. 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-675.
21. Ockenga J, Tillmann HL, Trautwein C, et al. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997; 27: 18-24.
22. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
23. Lin R, Roach E, Zimmerman M, et al. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. J Hepatol 1995; 23: 487-496.
24. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
25. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997; 26 (Suppl 1): 2S-10S.
26. Lin R, Liddle C, Byth K, Farrell GC. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepatitis 1996; 3: 85-96.
27. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse effects in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47.
28. Davis GL, Esteban-Mur R, Rustgi V, et al. Recombinant interferon alfa-2b (Intron A) alone or in combination with ribavirin (Rebetol) for retreatment of interferon relapse in chronic hepatitis C. N Engl J Med (submitted).
29. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215.
30. Levy MT, Chen JJ, McGuinness PH, et al. Liver transplantation for hepatitis C-associated cirrhosis in a single Australian centre: referral patterns and transplant outcomes. J Gastroenterol Hepatol 1997; 12: 453-459.
31. Williams R, Rizzi P. Treating small hepatocellular carcinomas. N Engl J Med 1996; 334: 728-729.